Business Wire

BOC-GROUP

15.1.2020 15:29:10 CET | Business Wire | Press release

Share
BOC Group and TIM Solutions Announce Strategic Partnership to Deliver Accelerated Digitalization of Business Processes

BOC Group , a global leader in enterprise business process analysis software (EBPA), and TIM Solutions , a leading provider of business process management (BPM) software for low-code human workflow automation, announced their strategic partnership today, focused on delivering accelerated digitalization of Business Process Automation at the enterprise level.

Both BOC Group and TIM have experienced that rapid automation of an existing manual process is the key first step in successful delivery of process automation. Once the automation is up-and-running, process analysis and design ensure that the process is quickly optimized further to reach cost reduction efficiencies of up-to 80%. What’s more, this approach delivers on all key targets of automation – reduction of redundant process activities, digitalization of manual tasks, and the overall improvement of customer experience. By combining TIM’s process automation with ADONIS’ process design and analysis capabilities, organizations can expect both a shorter time-to-value when automating processes, and a higher value-add delivered by the optimally designed automation.

The past months of collaboration between TIM and BOC Group have culminated today in a meeting of both management teams at BOC Group’s headquarters in Vienna, Austria, where the release of the ADONIS Process Automation module on the BOC Marketplace was announced. Customers of both partners can now benefit from this native integration that combines the intuitive process design, analysis and simulation of ADONIS with the seamless deployment, automation and monitoring of business processes in TIM’s process automation platform.

“Our customers seek to use low-code process automation as a key step in their digital journey. TIM is uniquely positioned as a simple, powerful and cost-effective automation platform that allows our customers to turn their process designs into automated workflows” mentioned Dr. Harald Kühn, BOC Group Board member. “We are excited about ADONIS Process Automation, powered by TIM, going live today on the BOC Marketplace” added Dr. Kühn.

“Having an optimal process design is a key success factor in rolling-out an automated human workflow. We are certain that the process analysis and design capabilities of ADONIS will be greatly beneficial when designing and optimizing automated workflows.” said TIM Solutions CEO, Mr. Hermann Filss “We are excited to be partnering with BOC Group as we look to directly profit from their global client footprint and rapidly spread the use of TIM around the world,” added Mr. Filss.

Both vendors have kicked-off campaigns to roll-out the integration as they look to capture a very active process automation market with their unique combined offering. Interested parties are welcome to schedule a Proof of Concept through the BOC Marketplace .

About BOC Group

BOC is a global leader in Enterprise Modelling Software across the Enterprise Business Process Analysis (EBPA), Governance Risk and Compliance (GRC) and Enterprise Architecture (EA) domains. Enabling customers to successfully and continuously re-design their digital enterprise to ensure business success at every level of the organization.

ADONIS customers include:

  • Allianz
  • Comcast
  • Emerson
  • Hilti
  • Telefonica

BOC delivers products and services globally to over 1,000 companies supported by over 90 partners around the globe.

About TIM Solutions

TIM Solutions is focused on developing a simple method for automating and managing human workflows. They provide comprehensive solutions and consulting to their customers in the field Business Process Automation and Business Process Management.

TIM customers include:

  • BMW AG
  • Deutsche Bahn AG
  • ManpowerGroup
  • E.ON SE
  • Tata Consultancy Services

TIM BPM Suite is used by more than 310 companies in 56 countries around the globe.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release

Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye